Literature DB >> 8234164

Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery.

D L French1, J W Mauger.   

Abstract

The physicochemical properties of mesalamine and the effect of pH and buffer concentration on the dissolution rate of pure mesalamine and mesalamine with Carbopol 974P were investigated. The aqueous solubilities at 25 and 37 degrees C were 0.844 and 1.41 mg/mL, respectively. Consistent with the observed pKa1 (2.30) and pKa2 (5.69) or mesalamine, the solubility-pH profile is increased at pH < 2.0 and pH > 5.5 and is minimized from pH 2.0 to pH 5.5. The flux data were consistent with the solubility data from pH 1.0 to pH 5.5. The flux increased and plateaued at pH values 5.5 to 7.0 and was dependent on the bulk buffer concentration. At low bulk buffer concentrations, mesalamine reduces the pH in the diffusion layer, which results in a decrease in flux. The medium with the highest buffer capacity has a greater ability to increase the surface pH and dissolution rate. The addition of Carbopol reduces the flux and the sensitivity of the dissolution rate of mesalamine to increasing bulk buffer concentration. This reduction is postulated to be due to neutralization of the basic dissolution media, gel formation, and possible drug-polymer interactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8234164     DOI: 10.1023/a:1018909527659

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  Interaction studies of cationic drugs with anionic polyelectrolytes. II. Polyacrylic and styrene polymers.

Authors:  L KENNON; T HIGUCHI
Journal:  J Am Pharm Assoc Am Pharm Assoc       Date:  1957-01

2.  Microviscosity and drug release from topical gel formulations.

Authors:  K I Al-Khamis; S S Davis; J Hadgraft
Journal:  Pharm Res       Date:  1986-08       Impact factor: 4.200

3.  Acute pancreatitis due to 5-aminosalicylate.

Authors:  B Sachedina; F Saibil; L B Cohen; J Whittey
Journal:  Ann Intern Med       Date:  1989-03-15       Impact factor: 25.391

4.  Nephrotic syndrome after treatment with 5-aminosalicylic acid.

Authors:  B H Novis; Z Korzets; P Chen; J Bernheim
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

5.  Diffusion and concentration profiles of drugs in gels.

Authors:  S M Upadrashta; B O Häglund; L O Sundelöf
Journal:  J Pharm Sci       Date:  1993-11       Impact factor: 3.534

6.  Dissolution of carboxylic acids. III: The effect of polyionizable buffers.

Authors:  J G Aunins; M Z Southard; R A Myers; K J Himmelstein; V J Stella
Journal:  J Pharm Sci       Date:  1985-12       Impact factor: 3.534

7.  Dissolution kinetics of carboxylic acids I: effect of pH under unbuffered conditions.

Authors:  K G Mooney; M A Mintun; K J Himmelstein; V J Stella
Journal:  J Pharm Sci       Date:  1981-01       Impact factor: 3.534

8.  Studies on powdered preparation. XVII. Dissolution rate of sulfonamides by rotating disk method.

Authors:  H Nogami; T Nagai; A Suzuki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1966-04       Impact factor: 1.645

9.  Dissolution kinetics of carboxylic acids II: effect of buffers.

Authors:  K G Mooney; M A Mintun; K J Himmelstein; V J Stella
Journal:  J Pharm Sci       Date:  1981-01       Impact factor: 3.534

10.  Pancreatitis after rectal administration of 5-aminosalicylic acid.

Authors:  K L Isaacs; D Murphy
Journal:  J Clin Gastroenterol       Date:  1990-04       Impact factor: 3.062

  10 in total
  14 in total

1.  Once daily, high-dose mesalazine controlled-release tablet for colonic delivery: optimization of formulation variables using Box-Behnken design.

Authors:  Ahmed Abd Elbary; Ahmed A Aboelwafa; Ibrahim M Al Sharabi
Journal:  AAPS PharmSciTech       Date:  2011-10-29       Impact factor: 3.246

2.  Influence of some formulation variables on the optimization of pH-dependent, colon-targeted, sustained-release mesalamine microspheres.

Authors:  Ahmed Abd El-Bary; Ahmed A Aboelwafa; Ibrahim M Al Sharabi
Journal:  AAPS PharmSciTech       Date:  2011-12-01       Impact factor: 3.246

3.  Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.

Authors:  Rajkumar Malayandi; Phani Krishna Kondamudi; P K Ruby; Deepika Aggarwal
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

4.  Mesalamine: a rare constituent of urinary tract concretions.

Authors:  Mudhar N Hasan; Hans-Göran Tiselius
Journal:  Urolithiasis       Date:  2013-04-02       Impact factor: 3.436

Review 5.  Colon-targeted oral drug delivery systems: design trends and approaches.

Authors:  Seth Amidon; Jack E Brown; Vivek S Dave
Journal:  AAPS PharmSciTech       Date:  2015-06-13       Impact factor: 3.246

6.  Melt-Extruded Eudragit® FS-Based Granules for Colonic Drug Delivery.

Authors:  Feng Zhang
Journal:  AAPS PharmSciTech       Date:  2015-07-11       Impact factor: 3.246

7.  Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.

Authors:  Filippos Kesisoglou; Simon Yuji Zhou; Susan Niemiec; Jordan Wing Lee; Ellen M Zimmermann; David Fleisher
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

8.  Controlled release of substituted benzoic and naphthoic acids using Carbopol gels: measurement of drug concentration profiles and correlation to release rate kinetics.

Authors:  D L French; B O Häglund; K J Himmelstein; J W Mauger
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

9.  Modelling and Simulation of the Drug Release from a Solid Dosage Form in the Human Ascending Colon: The Influence of Different Motility Patterns and Fluid Viscosities.

Authors:  Michael Schütt; Konstantinos Stamatopoulos; Hannah K Batchelor; Mark J H Simmons; Alessio Alexiadis
Journal:  Pharmaceutics       Date:  2021-06-10       Impact factor: 6.321

10.  Dextran Carrier Macromolecules for Colon-specific Delivery of 5-Aminosalicylic Acid.

Authors:  P K Shrivastava; A Shrivastava; S K Sinha; S K Shrivastava
Journal:  Indian J Pharm Sci       Date:  2013-05       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.